Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 9/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | BMP1 | P13497 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44456 | 0.89 | KIFC1 (0.37) | KIFC1AAK1KCNH2MAPTMAPK1 | |
| SCHEMBL44304 | 0.83 | KCNH2 (0.43) | KIFC1AAK1KCNH2MAPTMAPK1 | |
| SCHEMBL16592816 | 0.83 | MAOA (0.35) | MAPTSMN1; SMN2NPC1RAB9A | |
| SCHEMBL44298 | 0.82 | POLB (0.45) | MAPT | |
| SCHEMBL43972 | 0.81 | HTT (0.53) | KIFC1AAK1KCNH2MAPTMAPK1 | |
| SCHEMBL46474 | 0.80 | L3MBTL1 (0.40) | MAPTSMN1; SMN2S1PR1NPC1RAB9A | |
| SCHEMBL16592861 | 0.79 | AAK1 (0.38) | KIFC1AAK1KCNH2MAPTMAPK1 | |
| SCHEMBL993694 | 0.78 | L3MBTL1 (0.34) | AAK1MAPTSMN1; SMN2S1PR1HTT | |
| SCHEMBL44457 | 0.78 | MAPT (0.43) | MAPT | |
| SCHEMBL44476 | 0.76 | GAA (0.37) | MAPTSMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2214669-B1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-04-01 | — | — | EP | claimed |
| WO-2011137587-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-11-10 | — | — | WO | claimed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | claimed |
| EP-2214669-A1 | CYTOKINE INHIBITORS | Hutchison Medipharma Enterprises Limited (BS) | 2010-08-11 | — | — | EP | claimed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | claimed |
| WO-2009059162-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-05-07 | — | — | WO | claimed |
| EP-2214669-B1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2015-04-01 | — | — | EP | disclosed |
| WO-2011137587-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-11-10 | — | — | WO | disclosed |
| US-7868001-B2 | Cytokine inhibitors | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2011-01-11 | — | — | US | disclosed |
| EP-2214669-A1 | CYTOKINE INHIBITORS | Hutchison Medipharma Enterprises Limited (BS) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (CN) | 2009-05-07 | — | — | US | disclosed |
| WO-2009059162-A1 | CYTOKINE INHIBITORS | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118292-A1 | such as 2-(3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)imidazo[1,2-b]pyridazine, used for decreasing the levels of tumor necrosis factors or interleukines; treatment of inflammation, autoimmune diseases, diabetes, atherosclerosis and cancer | IL1B, IL1A, IL17A | KIFC1 3642/4885AAK1 173/4885KCNH2 2478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.